Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis.

Autor: Grempler R; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma Inc, 900 Ridgebury Road, Ridgefield, CT, 06877, USA. rolf.grempler@boehringer-ingelheim.com., Ahlberg J; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA., Germovsek E; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim am Rhein, Germany., Gupta P; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA., Li H; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA., Pilvankar M; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA., Sharma A; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma Inc, 900 Ridgebury Road, Ridgefield, CT, 06877, USA., Stopfer P; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach an der Riss, Germany., Hansel S; Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharma Inc, Connecticut, USA.

Publikováno v: Advances in therapy [Adv Ther] 2024 Jan; Vol. 41 (1), pp. 364-378. Date of Electronic Publication: 2023 Nov 16.

A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations.

Autor: Germovsek E; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden., Hansson A; McNeil AB, Helsingborg, Sweden., Karlsson MO; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden., Westin Å; McNeil AB, Helsingborg, Sweden., Soons PA; Janssen R&D - A Division of Janssen Pharmaceutica NV, Beerse, Belgium., Vermeulen A; Janssen R&D - A Division of Janssen Pharmaceutica NV, Beerse, Belgium., Kjellsson MC; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Feb; Vol. 109 (2), pp. 416-423. Date of Electronic Publication: 2020 Sep 19.

What do I need to know about aminoglycoside antibiotics?

Autor: Germovsek, E, Barker, CI, Sharland, M

The aminoglycosides are broad-spectrum, bactericidal antibiotics that are commonly prescribed for children, primarily for infections caused by Gram-negative pathogens. The aminoglycosides include gentamicin, amikacin, tobramycin, neomycin, and strept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::b28eab8deaee9fc168e66ac615523866
https://openaccess.sgul.ac.uk/id/eprint/108101/1/ADC-Aminoglycosides-20160411-final-accepted.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.

Autor: Pearson AD; ACCELERATE, Europe. Electronic address: andy1pearson@btinternet.com., DuBois SG; Dana-Farber Cancer Institute/Harvard Medical School, USA., Buenger V; Coalition Against Childhood Cancer, USA., Kieran M; Bristol Myers Squibb, USA., Stegmaier K; Dana-Farber Cancer Institute/Harvard Medical School, USA., Bandopadhayay P; Dana-Farber Cancer Institute/Harvard Medical School, USA., Bennett K; AbbVie, USA., Bourdeaut F; Institut Curie, France., Brown PA; Johns Hopkins Kimmel Cancer Center, USA., Chesler L; The Institute of Cancer Research, UK., Clymer J; Dana-Farber Cancer Institute/Harvard Medical School, USA., Fox E; St Jude Children's Research Hospital, USA., French CA; Brigham and Women's Hospital/Harvard Medical School, USA., Germovsek E; Boehringer Ingelheim Pharma GmbH & Co KG, Germany., Giles FJ; Developmental Therapeutics Consortium, USA., Bender JG; Memorial Sloan Kettering Cancer Center, USA., Hattersley MM; AstraZeneca, USA., Ludwinski D; Solving Kids' Cancer, UK; Solving Kids' Cancer, USA., Luptakova K; Constellation Pharmaceuticals, USA., Maris J; Children's Hospital of Philadelphia, USA., McDonough J; The Andrew McDonough B+ Foundation, USA., Nikolova Z; Celgene International, a Bristol Myers Squibb Company, Switzerland., Smith M; National Cancer Institute, USA., Tsiatis AC; Plexxikon, USA., Vibhakar R; University of Colorado and Children's Hospital Colorado, USA., Weiner S; Children's Cancer Cause, USA., Yi JS; Texas Children's Hospital/Baylor College of Medicine, USA., Zheng F; Incyte, USA., Vassal G; ACCELERATE, Europe; Gustave Roussy, France.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Mar; Vol. 146, pp. 115-124. Date of Electronic Publication: 2021 Feb 16.